SCHEMBL2195276

SCHEMBL2195276

Cn1c(=[Pt])n(C)c2ccccc21.FC(F)(F)c1ccc(CN(I)I)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.39
MTOR P42345 1/20 0.39
PYCR1 P32322 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR6 P50406 1/20 0.38
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
PDE2A O00408 1/20 0.34
LSS P48449 1/20 0.34
DRD4 P21917 2/20 0.34
GRM2 Q14416 2/20 0.34
DNM1 Q05193 1/20 0.33
NR3C1 P04150 1/20 0.33
DRD2 P14416 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
ALOX15B O15296 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194917 0.85 KIF11 (0.39) KIF11MTORPYCR1MEN1KMT2A
SCHEMBL2196746 0.84 TSPO (0.39) PYCR1MEN1KMT2AL3MBTL1
SCHEMBL2192488 0.84 ALDH1A1 (0.39)
SCHEMBL2196641 0.82 NPC1 (0.38) PYCR1MEN1KMT2AHTR6
SCHEMBL2194557 0.81 PYCR1 (0.41) MTORPYCR1MEN1KMT2ASLC6A2
SCHEMBL2195641 0.81 RAB9A (0.40) MEN1KMT2AHTR6LSS
SCHEMBL2192106 0.81 CXCR3 (0.46) PYCR1MEN1KMT2AL3MBTL1
SCHEMBL2196965 0.81 ALOX15B (0.39) MTORPYCR1MEN1KMT2ASLC6A2
SCHEMBL2195071 0.79 CYP19A1 (0.36) KIF11MTORPYCR1MEN1KMT2A
SCHEMBL2193845 0.76 POLB (0.39) MTORHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 KIF11 3398/4885MTOR 3689/4885PYCR1 75/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 KIF11 3398/4885MTOR 3689/4885PYCR1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.